22-Hydroxy-3-oxoolean-12-en-29-oic acidCAS# 144629-84-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 144629-84-5 | SDF | Download SDF |
PubChem ID | 71307356 | Appearance | Powder |
Formula | C30H46O4 | M.Wt | 470.7 |
Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (4aR,6aR,6aS,6bR,12aR,14bR)-4-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxo-3,4,5,6,6a,7,8,8a,11,12,13,14b-dodecahydro-1H-picene-2-carboxylic acid | ||
SMILES | CC1(C2CCC3(C(C2(CCC1=O)C)CC=C4C3(CCC5(C4CC(CC5O)(C)C(=O)O)C)C)C)C | ||
Standard InChIKey | RUJQEBHXYLCSKV-RKBHPYEFSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
22-Hydroxy-3-oxoolean-12-en-29-oic acid Dilution Calculator
22-Hydroxy-3-oxoolean-12-en-29-oic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.1245 mL | 10.6225 mL | 21.245 mL | 42.4899 mL | 53.1124 mL |
5 mM | 0.4249 mL | 2.1245 mL | 4.249 mL | 8.498 mL | 10.6225 mL |
10 mM | 0.2124 mL | 1.0622 mL | 2.1245 mL | 4.249 mL | 5.3112 mL |
50 mM | 0.0425 mL | 0.2124 mL | 0.4249 mL | 0.8498 mL | 1.0622 mL |
100 mM | 0.0212 mL | 0.1062 mL | 0.2124 mL | 0.4249 mL | 0.5311 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- GR 113808
Catalog No.:BCC7019
CAS No.:144625-51-4
- CPI-203
Catalog No.:BCC4099
CAS No.:1446144-04-2
- Isomahanine
Catalog No.:BCN3177
CAS No.:144606-95-1
- Schisanlignone D
Catalog No.:BCN3630
CAS No.:144606-84-8
- Schisanlignone C
Catalog No.:BCN3629
CAS No.:144606-83-7
- IRL-1038
Catalog No.:BCC5730
CAS No.:144602-02-8
- Paliperidone
Catalog No.:BCC3834
CAS No.:144598-75-4
- Kanshone H
Catalog No.:BCN7627
CAS No.:1445952-33-9
- GSK 2837808A
Catalog No.:BCC5607
CAS No.:1445879-21-9
- ME0328
Catalog No.:BCC3995
CAS No.:1445251-22-8
- Murrayanol
Catalog No.:BCN3178
CAS No.:144525-81-5
- Oxyresveratrol 3'-O-beta-D-glucopyranoside
Catalog No.:BCN1566
CAS No.:144525-40-6
- (+)-Lyoniresinol
Catalog No.:BCN6248
CAS No.:14464-90-5
- Olmesartan
Catalog No.:BCC1819
CAS No.:144689-24-7
- Olmesartan medoxomil
Catalog No.:BCC2143
CAS No.:144689-63-4
- Hispidulin
Catalog No.:BCN6250
CAS No.:1447-88-7
- Fmoc-D-Cha-OH
Catalog No.:BCC3161
CAS No.:144701-25-7
- Telmisattan
Catalog No.:BCC3863
CAS No.:144701-48-4
- Telmisartan tert-butyl ester
Catalog No.:BCC9161
CAS No.:144702-26-1
- 4F 4PP oxalate
Catalog No.:BCC6678
CAS No.:144734-36-1
- 2-4-Hydroxy-3-methoxyphenyl-7-methoxy-5-benzofuranpropanol
Catalog No.:BCN1564
CAS No.:144735-57-9
- Cyclo(Phe-Val)
Catalog No.:BCN2419
CAS No.:14474-71-6
- Cyclo(Ala-Phe)
Catalog No.:BCN2411
CAS No.:14474-78-3
- Clopidogrel Related Compound B
Catalog No.:BCN2688
CAS No.:144750-52-7
The value of grip test, lysophosphatidlycholines, glycerophosphocholine, ornithine, glucuronic acid decrement in assessment of nutritional and metabolic characteristics in hepatitis B cirrhosis.[Pubmed:28384211]
PLoS One. 2017 Apr 6;12(4):e0175165.
The liver is essential for the regulation of energy, protein and amino acids, as well as in other aspects of metabolism. To identify efficient indexes for evaluation of nutritional status and metabolic characteristics during different Child-Pugh stages of hepatitis B cirrhosis, 83 patients and 35 healthy individuals were enrolled in our study. We found that grip strength, triceps skinfold thickness (TSF), body fat and skeletal muscle of the patients were reduced compared to the control group (P<0.05). Ultra-high-performance liquid chromatography data combined with mass spectrometry (UPLC-MS) showed that levels of a variety of metabolites, including lysophosphatidylcholines (LysoPCs), glycerophosphocholine, ornithine and glucuronic acid were reduced in the serum of patients with hepatitis B cirrhosis (P<0.001). However, glycerophosphoserine and taurocholic acid levels were higher than in the control group (P<0.001). Moreover, grip strength was correlated with the Child-Pugh score (P<0.05). Serum albumin, total cholesterol, LDL, LysoPCs, glycerophosphocholine, ornithine, glucuronic acid, glycerophosphoserine and taurocholic acid were correlated with the Child-Pugh score (P<0.01). These findings suggested that grip strength and the above small molecular substances might be considered as sensitive and important indexes for evaluating nutritional status and metabolic characteristics of patients with hepatitis B cirrhosis, which may help assess prognosis and adjust nutritional treatment.
Prevention of TGF-beta-induced early liver fibrosis by a maleic acid derivative anti-oxidant through suppression of ROS, inflammation and hepatic stellate cells activation.[Pubmed:28384213]
PLoS One. 2017 Apr 6;12(4):e0174008.
Current anti-fibrotic effect of antioxidants in vivo is disappointing due probably to the fact that once liver fibrogenesis is established it is too advanced to be reversed by anti-oxidation mechanism. We consider antioxidant may only act on the early phase of fibrogenesis. Thus, we had previously established an early liver fibrosis animal model using an inducible expression vector (pPK9a), which contains TGF-beta gene and was hydro-dynamically transferred into mice to induce a transient liver fibrosis. TGF-beta1 has been well documented to up-regulate the expression of alpha2(1) collagen (Col 1A2) gene in the liver via the reactive oxygen species (ROS); the process triggers inflammation, leading to hepatic stellate cells (HSC) activation and liver fibrogenesis. Using our animal model and ROS, cyclooxygenase-2 (Cox-2) and Col 1A2 promoter assays as screening targets, we report here that a maleic acid derivative isolated from the Antrodia camphorata mycelium strongly decreases ROS production, promoter activity of Cox-2 and Col 1A2, intracellular calcium, expression of alpha-smooth muscle actin (alpha-SMA), Smad4-p-Smad2/3 co-localization in cell nucleus and the DNA binding activity of Sp1. Our results suggest that the maleic acid derivative prevents liver fibrosis at an early phase both in vitro and in vivo through the inhibition of ROS, inflammation and the activation of HSC.
Thermo-acid-stable phytase-mediated enhancement of bioethanol production using Colocasia esculenta.[Pubmed:28384593]
Bioresour Technol. 2017 Jul;235:396-404.
Phytase production by the thermophilic mould Thermomyces lanuginosus SSBP was enhanced 8.56-fold in submerged fermentation, which was further improved in fed-batch cultivations. The protein was purified to homogeneity using ammonium sulphate precipitation, Resource Q anion exchange and Superdex gel-filtration chromatography, with an overall purification of 24.7-fold and a yield of 5.16%. The purified 49kDa protein was optimally active at 55 degrees C and pH 5.0, and was stable between 50 and 90 degrees C from pH 3.0-6.0, with a half-life of 138.6min at 70 degrees C. It was moderately stimulated by Ba(+2) and Mg(+2). The enzyme reduced phytate content in Colocasia esculenta starch (from 1.43mg/g to 0.05mg/g) that resulted in an improvement in the availability of fermentable sugars with a concomitant reduction in viscosity and 1.59-fold improvement in ethanol production. Thermo-acid-stable phytase from T. lanuginosus SSBP could be of major biotechnological interest, especially due to its robustness and wide applicability.